Notice Number: NOT-AI-16-051

Key Dates
Release Date: April 11, 2016

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to inform potential applicants of a change in the purpose in the funding opportunity announcement (FOA) RFA-AI-16-009 titled "NIAID SBIR-Technology Transfer Direct Phase II (R44)".

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Purpose

Current language:
This FOA applies to vaccine and treatment inventions originating from the NIAID intramural laboratories for which the US Government has various levels of patent protection for their use in treatment and prevention.  The inventions include:

• HIV anti-gp120 env vaccine as a therapeutic or HIV prevention vaccine,
• HPV virus-like particles as a vaccine delivery system and adjuvant,
• Malaria p47 protein for use as a vaccine or as product therapeutic antibodies,
• Methicillin-resistant Staphylococcus aureus (MRSA) phenol soluble proteins (PSM) for use as a vaccine immunogen,
• Norovirus (Norwalk) antibodies for treatment and prevention of virus disease,
• Strongyliodes (S. stercoralis) immunoreactive antigen (SsIR) for use as therapeutic or preventive vaccine,
• Use of the 10E8 broadly neutralizing antibody for HIV treatment and prevention,
• Methods to induce anti-HIV CD8 activity:
  • Methods for use of chimeric antigen receptor (CAR),
  • Methods for CD8 reactivation using PBMCs from AIDS-infected individuals,  
• Use of octameric anthrax protective antigen protein (PA) for treatment of cancers and infectious diseases.

For more details on these inventions, please see a list of eligible inventions.

New language reflecting the deletion of the bullet regarding the 10E8 broadly neutralizing antibody:
This FOA applies to vaccine and treatment inventions originating from the NIAID intramural laboratories for which the US Government has various levels of patent protection for their use in treatment and prevention.  The inventions include:

• HIV anti-gp120 env vaccine as a therapeutic or HIV prevention vaccine,
• HPV virus-like particles as a vaccine delivery system and adjuvant,
• Malaria p47 protein for use as a vaccine or as product therapeutic antibodies,
• Methicillin-resistant Staphylococcus aureus (MRSA) phenol soluble proteins (PSM) for use as a vaccine immunogen,
• Norovirus (Norwalk) antibodies for treatment and prevention of virus disease,
• Strongyliodes (S. stercoralis) immunoreactive antigen (SsIR) for use as therapeutic or preventive vaccine,
• Methods to induce anti-HIV CD8 activity:
  • Methods for use of chimeric antigen receptor (CAR),
  • Methods for CD8 reactivation using PBMCs from AIDS-infected individuals,  
• Use of octameric anthrax protective antigen protein (PA) for treatment of cancers and infectious diseases.

For more details on these inventions, please see a list of eligible inventions.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Natalia Kruchinin, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-2919
Email: kruchininn@niaid.nih.gov